Prostate, Ovarian, Pancreatic, Cancer
In this video, John Hall spends about 27 minutes speaking on "Prostate, Ovarian, Pancreatic, Cancer" at the 40th Annual Cancer Convention held on Labor Day weekend by the Cancer Control Society.
About John Hall
JOHN HALL, Ph.D. completed his undergraduate studies at Columbia University, New York City with a B.S. Degree in Organic Chemistry. He was a Graduate Fellow at Princeton University, New Jersey working within the Department of Biochemical Sciences and he completed his Ph.D. Degree at New York University, New York City in the Department of Biochemistry. Dr. Hall was awarded a Postdoctoral Fellowship in Dr. David Luck's Laboratory at Rockefeller University, New York City researching Cell Biology. He was promoted to the Faculty at Rockefeller in 1989, where his research focused on the microtubule-based mechanisms of cell motility and cell division and the connection between cell motility and cancer. Dr. Hall has served as an Executive and as a Consultant in the Biotechnology Industry and is currently the Director of Research at Natural Source International, Ltd in New York City, which specializes in the Beljanski Products. He may be reached through the Company by phone 212-308-7066, e-mail [email protected] and website www.natural-source.com.
Transcription
Back to you. Good morning, everyone.
I'm delighted to be back. And I want to make a point of thanking Frank and Lorraine for inviting us back this year.
Fortunately, I have some new stuff to talk about, and Frank gave part of my title. In fact, it's a new approach to prostate, ovarian and pancreatic cancers, as he said on the director of research at Natural Source International.
And I've had a career in academic biomedical research and I'm now working with this biotech company, Natural Source.
Well, I think there's not going to be much controversy about the idea that a new approach to these cancers I've mentioned is worthwhile and sorely needed for prostate, advanced prostate. This is now and ovarian and pancreatic cancer is the mainstream. Treatments do not really have much effect on the overall outcome of the patients in terms of quality of life and length of life. So we've been very interested in trying to find a way to do something about that, which makes use of this scientific history that we possess at the company.
Now, this article here I have it published in Fortune is actually a few years old. And I showed it just to point out that course we're losing one cancer, particularly these three. They're great examples of ones that have not been amenable to the kinds of treatments that the pharmaceutical industry has pursued.
But in this article, they also point out, well, what would be better, what's where we're what are we looking for in an effective treatment? And of course, it's one that works, but it's one that's more selective. Meaning cancer cells are more effectively targeted and normal cells are spared.
And also then an absence of negative side effects is extremely desirable. Well, let me just spend a minute and talk about how we got into this situation from a scientific research perspective. There are two fundamental ways to look at the DNA molecule. And the speaker, just before we talked about scientists now looking at the effect of different food products on DNA. And I'm going to focus more closely on the effect of carcinogens on DNA. The DNA is everybody knows you've got to be looking there to find the secrets, the carcinogenesis. But what exactly what aspect of the DNA should we be focusing on? Well, first, let's talk about a consensus, which is I think 100 percent of the DNA is the repository of genetic material. That's where our genes are. The genes code for proteins. The proteins are the products that make up our bodies. Defects in proteins have consequences. They can at times cause deregulation of cell